Angiogenic therapy for Chronic Ischemic Myocardium with Platelet-derived Endothelial Cell Growth Factor Gene in aDog Model

2001 Fiscal Year Final Research Report Summary

• Project/Area Number: 12671303
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Thoracic surgery
• Research Institution: Fukui Medical University
• Principal Investigator: CHIBA Yukio Fukui Medical University 2nd department of surgery, assistant professor, 医学部, 助教授 (30111959)
• Co-Investigator(Kenkyū-buntansha): KIMURA Tetsuya Fukui Medical University 2nd department of surgery, assistant, 医学部, 助手 (50195369)
• Project Period (FY): 2000 – 2001
• Keywords: PD-ECGFAT / angiogenesis / schemic myocardium / apptosis / 遺伝子治療 / apoptosis

Research Abstract

Angiogenesis is a promising novel therapeutic strategy to provide new venues for blood flow in patients with severe ischemic heart arid peripheral vascular disease, who are not candidates for standard revascularization strategies.
Platelet-derived endothelial cell gro\yth factor (PD-ECGF) is also identical to thymidine phosphorylase (TP), catalyze the reversible phosphorolysis of thymidine to thymine and 2'-deoxy-D-ribose-1-phosphate. PD-ECGFfTP has been shown to possess angiogenic activity in and confers resistance to apoptosis induced by hypoxia.
This study examine the effectiveness of delivery a mammalian expression plasmid vector encoding human full length PD-ECGF/TP complementary DNA in the chronic canine ischemic myocardium. We found that injecting of PD-ECGF/TP gene not only induced angiogenesis, myocardiac function improvement, but also inhibited the apoptosis of the myocardial cells. The platelet-derived endothelial cell growth factor may be a influential candidate gene for gene therapeutic angibgenesis.